Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response

• Published in: American journal of hypertension Vol. 15; no. 5; pp. 389 - 393
• Main Authors: Kurland, Lisa, Melhus, Håkan, Karlsson, Julia, Kahan, Thomas, Malmqvist, Karin, Öhman, Peter, Nyström, Fredrik, Hägg, Anders, Lind, Lars
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01.05.2002
• Subjects: aldosterone synthase; CYP11B2; Genetics; hypertension; treatment; treatment; Genetics; aldosterone synthase; CYP11B2; hypertension
• ISSN: 0895-7061; 1941-7225; 1879-1905
• DOI: 10.1016/S0895-7061(02)02256-2

Background: Our aim was to determine whether the aldosterone synthase (CYP11B2) -344 C/T polymorphism was associated with the blood pressure (BP)-lowering response to antihypertensive treatment. Methods: Patients with mild-to-moderate primary hypertension and left ventricular hypertrophy were randomized in a double-blind study to receive treatment with either the angiotensin II type 1 (AT1) receptor antagonist irbesartan (n = 43), or the β1-adrenergic receptor blocker atenolol (n = 43). The aldosterone synthase (CYP11B2) -344 C/T polymorphism was analyzed using solid-phase minisequencing and related to BP reduction after 3 months treatment. Serum aldosterone levels were measured. Results: After 3 months treatment the mean reductions in BP were similar for both treatment groups. When assessing the systolic BP reduction in the irbesartan group, patients with the TT variant had a more pronounced reduction (−21 ± 19 SD mm Hg, n = 17) than both the TC (−14 ± 18 mm Hg, n = 18) and CC (0 ± 17 mm Hg, n = 8) genotypes (P = .04). There was no association between this polymorphism and the diastolic BP response. The -344 C/T polymorphism was not associated with the BP response to atenolol. Nor was it related to the baseline serum aldosterone level. Conclusions: The aldosterone synthase -344 C/T polymorphism was related to the BP-lowering response in hypertensive patients treated with the AT1-receptor antagonist irbesartan.